576 related articles for article (PubMed ID: 36444790)
1. Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: Design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR/Topo-1 inhibition.
Halim PA; Sharkawi SMZ; Labib MB
Bioorg Chem; 2023 Feb; 131():106273. PubMed ID: 36444790
[TBL] [Abstract][Full Text] [Related]
2. Characterization of novel heterocyclic compounds based on 4-aryl-4H-chromene scaffold as anticancer agents: Design, synthesis, antiprofilerative activity against resistant cancer cells, dual β-tubulin/c-Src inhibition, cell cycle arrest and apoptosis induction.
Abdelall EKA; A H Elshemy H; Labib MB; E A Mohamed F
Bioorg Chem; 2022 Mar; 120():105591. PubMed ID: 34998122
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis of novel chromene-based scaffolds targeting hepatocellular carcinoma: Cell cycle arrest, cytotoxic effect against resistant cancer cells, apoptosis induction, and c-Src inhibition.
Abdelall EKA; Elshemy HAH; Labib MB; Mohamed FEA
Drug Dev Res; 2024 Feb; 85(1):e22133. PubMed ID: 37971069
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, modeling studies and biological evaluation of pyrazole derivatives linked to oxime and nitrate moieties as nitric oxide donor selective COX-2 and aromatase inhibitors with dual anti-inflammatory and anti-neoplastic activities.
A A Fadaly W; A M M Elshaier Y; T M Nemr M; R A Abdellatif K
Bioorg Chem; 2023 May; 134():106428. PubMed ID: 36893546
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and molecular docking study of new pyrimidine-based hydrazones with selective anti-proliferative activity against MCF-7 and MDA-MB-231 human breast cancer cell lines.
Badawi WA; Samir M; Fathy HM; Okda TM; Noureldin MH; Atwa GMK; AboulWafa OM
Bioorg Chem; 2023 Sep; 138():106610. PubMed ID: 37210828
[TBL] [Abstract][Full Text] [Related]
6. Annulated pyrazole derivatives as a novel class of urokinase (uPA) inhibitors: Green synthesis, anticancer activity, DNA-damage evaluation, and molecular modelling study.
Farag PS; AboulMagd AM; Hemdan MM; Hassaballah AI
Bioorg Chem; 2023 Jan; 130():106231. PubMed ID: 36335649
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
Shaheen MA; El-Emam AA; El-Gohary NS
Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
9. New pyranopyrazole based derivatives: Design, synthesis, and biological evaluation as potential topoisomerase II inhibitors, apoptotic inducers, and antiproliferative agents.
Sobh EA; Kassab AE; El-Khouly EA; S A Hassan M
Bioorg Chem; 2024 Mar; 144():107158. PubMed ID: 38301427
[TBL] [Abstract][Full Text] [Related]
10. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
[TBL] [Abstract][Full Text] [Related]
11. Novel Pyrimidine-5-Carbonitriles as potential apoptotic and antiproliferative agents by dual inhibition of EGFR
Reda N; Mohamed KO; Abdou K; Helwa AA; Elshewy A
Bioorg Chem; 2024 Apr; 145():107185. PubMed ID: 38350273
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and molecular docking of novel pyrazole-chalcone analogs of lonazolac as 5-LOX, iNOS and tubulin polymerization inhibitors with potential anticancer and anti-inflammatory activities.
Ahmed AHH; Mohamed MFA; Allam RM; Nafady A; Mohamed SK; Gouda AE; Beshr EAM
Bioorg Chem; 2022 Dec; 129():106171. PubMed ID: 36166898
[TBL] [Abstract][Full Text] [Related]
13. Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives.
Alkamaly OM; Altwaijry N; Sabour R; Harras MF
Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000351. PubMed ID: 33252142
[TBL] [Abstract][Full Text] [Related]
14. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
16. New 1,2,4-triazole/pyrazole hybrids linked to oxime moiety as nitric oxide donor celecoxib analogs: Synthesis, cyclooxygenase inhibition anti-inflammatory, ulcerogenicity, anti-proliferative activities, apoptosis, molecular modeling and nitric oxide release studies.
Fadaly WAA; Elshaier YAMM; Hassanein EHM; Abdellatif KRA
Bioorg Chem; 2020 May; 98():103752. PubMed ID: 32197148
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and evaluation of new quinazolin-4-one derivatives as apoptotic enhancers and autophagy inhibitors with potent antitumor activity.
ElZahabi HSA; Nafie MS; Osman D; Elghazawy NH; Soliman DH; El-Helby AAH; Arafa RK
Eur J Med Chem; 2021 Oct; 222():113609. PubMed ID: 34119830
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel indanone containing spiroisoxazoline derivatives with selective COX-2 inhibition as anticancer agents.
Abolhasani H; Zarghi A; Komeili Movahhed T; Abolhasani A; Daraei B; Dastmalchi S
Bioorg Med Chem; 2021 Feb; 32():115960. PubMed ID: 33477020
[TBL] [Abstract][Full Text] [Related]
19. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
